New trial aims to beat cancer fatigue with common drug

NCT ID NCT07543536

Recruiting now Symptom relief Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests whether megestrol acetate, a drug often used for appetite loss, can prevent or reduce severe tiredness in 132 women with advanced breast cancer who are starting a treatment called trastuzumab deruxtecan (T-DXd). Participants will receive either megestrol acetate or a placebo, and researchers will track fatigue levels and quality of life over time. The goal is to help patients feel better during cancer therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED/METASTATIC BREAST CANCER HER2+, LOW, OR ULTRALOW ADVANCED/METASTATIC BREAST CANCER

Contacts and locations

Locations

Sun yat-Sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
Sun yat-Sen University Cancer Center
NOT_YET_RECRUITING

Guangzhou, Yuexiu District, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.